Eduardo H. Genofre

ORCID: 0000-0003-3782-4743
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pleural and Pulmonary Diseases
  • Asthma and respiratory diseases
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Respiratory Support and Mechanisms
  • Pneumothorax, Barotrauma, Emphysema
  • Trauma Management and Diagnosis
  • Respiratory and Cough-Related Research
  • Lung Cancer Diagnosis and Treatment
  • Lymphatic Disorders and Treatments
  • Diagnosis and treatment of tuberculosis
  • Ultrasound in Clinical Applications
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Pharmaceutical studies and practices
  • Healthcare Regulation
  • Eosinophilic Esophagitis
  • Muscle and Compartmental Disorders
  • Pericarditis and Cardiac Tamponade
  • Non-Invasive Vital Sign Monitoring
  • Periodontal Regeneration and Treatments
  • Clinical Laboratory Practices and Quality Control
  • Congenital Diaphragmatic Hernia Studies
  • Knee injuries and reconstruction techniques
  • Renal function and acid-base balance
  • Abdominal Surgery and Complications
  • Management of metastatic bone disease

AstraZeneca (United States)
2023-2024

AstraZeneca (Brazil)
2022-2023

AstraZeneca (Switzerland)
2023

Wilmington University
2021

AstraZeneca (Sweden)
2017-2019

Universidade de São Paulo
2002-2012

Universidade Brasil
2006-2012

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2003-2011

Pulmonary Associates
2011

Central Bela Vista (Brazil)
2009

ABSTRACT Background and objective: Tuberculosis (TB) cancer are two of the main causes pleural effusions which frequently share similar clinical features fluid profiles. This study aimed to identify diagnostic models based on laboratory variables differentiate tuberculous from malignant effusions. Methods: A retrospective 403 patients (200 with TB; 203 cancer) was undertaken. Univariate analysis used select relevant composition. Variables β coefficients were define a numerical score...

10.1111/j.1440-1843.2009.01621.x article EN Respirology 2009-10-22

Vascular endothelial growth factor (VEGF) is known to increase vascular permeability and promote angiogenesis. It expressed in most types of pleural effusions. However, the exact role VEGF development effusions has yet be determined. The anti-VEGF mAb, bevacizumab, been used treatment cancer reduce local angiogenesis tumour progression. This study describes acute effects blockade on expression inflammatory cytokines fluid accumulation.One hundred twelve New Zealand rabbits received...

10.1111/j.1440-1843.2009.01628.x article EN Respirology 2009-10-08

Intrapleural instillation of talc is used to produce pleurodesis in cases recurrent malignant pleural effusions. The mechanisms by which produced remain unknown but may involve either injury or activation the mesothelium. aim current study was assess inflammatory response mesothelial cells an experimental model rabbits. A group 10 rabbits were injected intrapleurally with (200 mg.kg(-1)) and undiluted fluid collected after 6, 24 48 h for measurement interleukin (IL)-8, vascular endothelial...

10.1183/09031936.06.00037906 article EN European Respiratory Journal 2006-07-26

Intrapleural instillation of talc has been used in the treatment recurrent pleural effusions but can, rare instances, result respiratory failure. Side-effects seem to be related composition, size and inflammatory power particles. The aim this study was evaluate response intrapleural injection containing small particles (ST) or mixed (MT). 100 rabbits received talc, 50 with ST (median 6.41 μm) MT 21.15 μm); control group composed 35 rabbits. Cells, lactate dehydrogenase, C-reactive protein...

10.1183/09031936.00039209 article EN European Respiratory Journal 2009-08-13

To describe clinical and laboratory characteristics in patients with tuberculosis-related or lymphoma-related lymphocytic pleural effusions, order to identify the variables that might contribute differentiating between these diseases.This was a retrospective study involving 159 adult HIV-negative effusions (130 29 patients, respectively), treated October of 2008 March 2010 at Pleural Diseases Outpatient Clinic University São Paulo School Medicine Hospital das Clínicas Heart Institute, city...

10.1590/s1806-37132012000200006 article EN cc-by-nc Jornal Brasileiro de Pneumologia 2012-04-01

L. Antonangelo, F. S. Vargas, M. P. Acencio, A. Corá, R. Teixeira, E. H. Genofre and K. B. Sales Effect of temperature storage time on cellular analysis fresh pleural fluid samples Objective: Despite the methodological variability in preparation techniques for cytology, it is fundamental that cells should be preserved, permitting adequate morphological classification. We evaluated numerical changes specimens processed after at room or under refrigeration. Methods: Aliquots from 30 patients,...

10.1111/j.1365-2303.2011.00863.x article EN Cytopathology 2011-03-21

BACKGROUND: Clinical trials and real-world evidence (RWE) studies of biologics have demonstrated reduced exacerbations, decreased use oral corticosteroids (OCS), improvements in daily symptoms health-related quality life patients with severe eosinophilic asthma (SEA). OBJECTIVE: To compare direct health care costs associated biologic for the treatment SEA from a US third-party payer perspective. METHODS: We developed cost-minimization model to cost offsets 3 biologics–benralizumab,...

10.18553/jmcp.2023.23034 article EN Journal of Managed Care & Specialty Pharmacy 2023-10-05

Patients with eosinophilic severe asthma (SA) have an increased risk of exacerbations. Benralizumab is approved for SA, and there great value in understanding real-world effectiveness.The aim this analysis was to examine the effectiveness benralizumab a cohort subspecialist-treated US patients SA.CHRONICLE ongoing, noninterventional study adults SA receiving biologics, maintenance systemic corticosteroids, or those persistently uncontrolled by high-dose inhaled corticosteroids additional...

10.1016/j.rmed.2023.107285 article EN cc-by-nc-nd Respiratory Medicine 2023-06-07

Reexpansion pulmonary edema (RPE) is a rare, but frequently lethal, clinical condition. The precise pathophysiologic abnormalities associated with this disorder are still unknown, though decreased surfactant levels and pro-inflammatory status putative mechanisms. Early diagnosis crucial, since prognosis depends on early recognition prompt treatment. Considering the high mortality rates related to RPE, preventive measures best available strategy for patient handling. This review provides...

10.1590/s0102-35862003000200010 article EN Jornal de Pneumologia 2003-04-01

Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is a heterogenous condition with clinical features shared by both asthma and COPD.This online global survey of respiratory/allergy specialists primary care practitioners (PCPs) was performed to understand current approaches the differential diagnosis management asthma, COPD ACO.Respondents were recruited through: (a) physician respondent community (49,980 PCPs 7205 specialists); (b) market research agents; (c) experts; (d)...

10.1111/crj.13016 article EN The Clinical Respiratory Journal 2019-03-02

Light's criteria are frequently used to evaluate the exudative or transudative nature of pleural effusions. However, misclassification resulting from use has been reported, especially in setting diuretic patients with heart failure (HF). The objective this study was utility B-type natriuretic peptide (BNP) measurements as a diagnostic tool for determining cardiac aetiology effusions.Patients effusions attributable HF (n = 34), hepatic hydrothorax 10), due cancer 21) and tuberculosis 12) were...

10.1111/j.1440-1843.2011.01930.x article EN Respirology 2011-01-25

In spite of the progress in diagnostic methods, about 20% pleural effusions may remain without a proper diagnosis after use conventional exams. order to determine origin these effusions, alternative methods and invasive procedures shall be used aiming etiology undiagnosed institute most appropriate therapeutics.

10.1590/s1806-37132006000900007 article EN cc-by-nc Jornal Brasileiro de Pneumologia 2006-08-01

Benralizumab is a biologic add-on treatment for severe eosinophilic asthma that can reduce the rate of exacerbations, but data on associated medical utilization are scarce. This retrospective study evaluated economic value benralizumab by analyzing healthcare resource (HRU) and costs in large patient population US.Insurance claims (11/2016-6/2020) were analyzed. A pre-post design was used to compare exacerbation rates, HRU 12 months pre vs. post index (day after initiation). Patients aged...

10.1080/13696998.2023.2236867 article EN Journal of Medical Economics 2023-07-13
Coming Soon ...